Biologically Active Small Molecules

A highly mutagenic metabolite of the carcinogenic mycotoxin aflatoxin B1.

A melatonin metabolite first identified in rat brain that has antioxidant and free radical scavenging activities in several experimental models may be measured in plasma as an index of melatonin synthesis and metabolism.

A melatonin metabolite first identified in rat brain that has antioxidant and free radical scavenging activities in several experimental models may be measured in plasma as an index of melatonin synthesis and metabolism.

A melatonin metabolite first identified in rat brain that has antioxidant and free radical scavenging activities in several experimental models may be measured in plasma as an index of melatonin synthesis and metabolism.

A melatonin metabolite first identified in rat brain that has antioxidant and free radical scavenging activities in several experimental models may be measured in plasma as an index of melatonin synthesis and metabolism.

A 7,7-difluoroprostacyclin derivative that acts as a selective and highly potent agonist for the IP receptor (Ki = 0.561 nM) shows weaker affinity for EP receptors, with Ki values of &gt 100 nM for EP1-3 and &gt 10 nM for EP4.

A 7,7-difluoroprostacyclin derivative that acts as a selective and highly potent agonist for the IP receptor (Ki = 0.561 nM) shows weaker affinity for EP receptors, with Ki values of &gt 100 nM for EP1-3 and &gt 10 nM for EP4.

A 7,7-difluoroprostacyclin derivative that acts as a selective and highly potent agonist for the IP receptor (Ki = 0.561 nM) shows weaker affinity for EP receptors, with Ki values of &gt 100 nM for EP1-3 and &gt 10 nM for EP4.

A selective, orally bioavailable inhibitor of Akt1, 2, and 3 (Kis = 0.08, 2, and 2.6 nM, respectively) inhibits the proliferation of human cancer cell lines with Akt pathway activation and various cell lines derived from hematologic malignancies.

A selective, orally bioavailable inhibitor of Akt1, 2, and 3 (Kis = 0.08, 2, and 2.6 nM, respectively) inhibits the proliferation of human cancer cell lines with Akt pathway activation and various cell lines derived from hematologic malignancies.

A selective, orally bioavailable inhibitor of Akt1, 2, and 3 (Kis = 0.08, 2, and 2.6 nM, respectively) inhibits the proliferation of human cancer cell lines with Akt pathway activation and various cell lines derived from hematologic malignancies.

A selective, orally bioavailable inhibitor of Akt1, 2, and 3 (Kis = 0.08, 2, and 2.6 nM, respectively) inhibits the proliferation of human cancer cell lines with Akt pathway activation and various cell lines derived from hematologic malignancies.